Taste Receptors Regulation in CF Patients

Cystic Fibrosis Clinical Trial

— CFTaste  

Official title:

The Effects of Taste Receptors Regulation in Upper Airway Innate Immunity of CF Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04058340
• Other study ID #: RNN/154/16/KE
• Status: Recruiting
• Phase: N/A
• Start date: July 30, 2019
• Est. completion date: December 30, 2019

Study information

• Verified date: August 2019
• Source: Medical Universtity of Lodz
• Contact: Pawel Majak
• Phone: 600621878
• Email: pmajak[@]o2.pl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The project is intended to be realised in two phases. In the first stage, a case control study will be performed. In the second phase, double-blind, placebo controlled cross-over study will be conducted. The first stage it to compare innate immunity activation and Pseudomonas aeruginosa (Pa) expression between Pa positive and negative patients. In the second phase the effects of inhaled lactizole- TAS3R inhibitor will be assessed.

Description:

Three visits have been planned during the entire study. During the first visit, all patients included in the study will have the following procedures: questionnaire tests, lung function tests, taste perception tests (gustometry) and exfoliative cytology of the nasal mucosa.

Patients with confirmed Pseudomonas aeruginosa presence in the airways will be randomly assigned to the Lactizole-Placebo group and the Placebo-Lactizole group, with a recommendation to take laktizol (3 ml) for 3 weeks at the concentration determined during the preliminary examination, in the nebulization 2 times per day) or placebo (3ml 0.9% NaCl solution in nebulization 2 once a day). The first nebulization of the solution issued during the visit will take place during the visit; each patient will undergo a clinical and spirometric assessment after 20 minutes of observation from completed nebulization.

During the second visit (after 4 weeks from visit 1), the first visit procedures will be repeated for all patients. Patients in the Lactizole-Placebo group will be recommended to take a placebo for 4 weeks (3 ml of 0.9% NaCl solution in nebulization 2 once a day); on the other hand, patients from the Placebo-Lactizole group will be advised to take lactisol for 4 weeks (3 ml of the solution in the concentration determined during the preliminary examination, in the nebulization 2 once a day). The first nebulization of the solution issued during the visit will take place during the visit; each patient will undergo a clinical and spirometric assessment after 20 minutes of observation from completed nebulization.

During the third visit (after 4 weeks from visit 2), the first visit procedures will be repeated for all patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 30, 2019
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• ulmonary manifestations of cystic fibrosis

Exclusion Criteria:

• first positive result of inoculation from the airways, which according to the standard is associated with the need for antibiotic therapy

• contraindication to a biopsy of the nasal mucosa

• exacerbation requiring antibiotics

• diabetes, exposure to tobacco smoke

• other chronic diseases and clinical conditions which, according to the researcher, may influence the assessed parameters and the course of the study.

Temporary exclusion criteria

• acute respiratory infection within 2 weeks from 1, 2 and 3 visits of the study.

Related Conditions & MeSH terms

• Cystic Fibrosis

Intervention

Dietary Supplement:
• lactizole nebulization
Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)

Other:
• Placebo
0.9% NaCl solution in nebulization

Locations

Country	Name	City	State
Poland	Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland	Lodz

Sponsors (1)

Lead Sponsor	Collaborator
Medical Universtity of Lodz

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Pseudomonas aeruginosa abundance	Decrease of abundance of P. aeruginosa in throat swabs after nebulized lactizole . intervention. PCR testing for the presence of Pseudomonas aeruginosa genetic material (FTD Bacterial pneumoniae-HAP, Fast-track diagnostics Ltd., Malta)	Change from Baseline after 4 weeks of the intervention
Secondary	Change from Baseline in cystic fibrosis symptoms	Questionnaire (standardized questionnaire to assess the degree of control of cystic fibrosis symptoms). Polish version of the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) will be used	Change from Baseline after 4 weeks of the intervention
Secondary	Change from Baseline in Lung function test	Lung function test: spirometry will be performed in accordance with ERS / ATS standards	Change from Baseline after 4 weeks of the intervention
Secondary	Change from Baseline in Taste perception	Taste perception testing (gustometry): quantitative evaluation using a standardized TSTs diagnostic tool (Taste Strips, Burghart, Wedel, Germany	Change from Baseline after 4 weeks of the intervention
Secondary	Change from Baseline in Nasal ILC1, 2 and 3 cells	Nasal mucosa samples (Rhino-probe, ASI, Arlington, Texas). The assessment of the nasal mucosa material will include: percentage of ILC1, 2 and 3 cells (immunophenotyping and measurement by flow cytometry)	Change from Baseline after 4 weeks of the intervention
Secondary	Change from Baseline in Nasal cytokines expression	Nasal mucosa samples (Rhino-probe, ASI, Arlington, Texas). The assessment of the nasal mucosa material will include: mRNA expression for: Muc5b, Muc5ac, Beta-defensine, T1R3, T2Rs, selected cytokines (qPCR technique using self-designed primers)	Change from Baseline after 4 weeks of the intervention